

Press release, 2025-07-14 Malmö, Sweden

aXichem Strengthens its Patent Portfolio with First National Patent for aXivite in Supplements for Sports Performance

<u>aXichem AB</u> (publ), (aXichem), the developer of innovative food supplement ingredients, has obtained its first national patent for aXivite[®] (phenylcapsaicin) as a performance-enhancing ingredient in dietary supplements intended for physical training. The patent application was filed in 2023 with the title "Physical performance aid" and is based on efficacy data from studies conducted by aXichem. The studies mapped the effects of different doses of phenylcapsaicin on strength training performance, muscle damage, protein breakdown, metabolic response, and estimates of perceived exertion and recovery.

Torsten Helsing, CEO at aXichem comments:

"I'm pleased to add this strategically important patent to our strong portfolio and to move forward with applications for patent protection for aXivite in this market segment in the U.S., as well as in selected countries under the PCT/WIPO and EPO organizations respectively. With a growing demand for preworkout and endurance-enhancing supplements surging across North America and Europe, we see an increasing interest from supplement manufacturers eager to integrate aXivite[®] into next-generation performance formulas. This indicates a possible interesting commercial value for the patents protecting aXivite in this segment."

The patent is based on data from primarily two studies on phenylcapsaicin as a performanceenhancing ingredient, one published in *Journal of the International Society of Sports Nutrition* Volume 20, 2023 - Issue 1

<u>"Effects of different phenylcapsaicin doses on resistance training performance, muscle damage,</u> protein breakdown, metabolic response, ratings of perceived exertion, and recovery: a randomized, triple-blinded, placebo-controlled, crossover trial"

and in the other published in *Frontiers of Physiology*, Sec. Exercise Physiology, Volume 14 - 2023 "Effects of phenylcapsaicin on aerobic capacity and physiological parameters in active young males: a randomized, triple-blinded, placebo-controlled, crossover trial".

aXichem has, after the filing of the patent application, continued to investigate the exciting properties of aXivite and in March 2025 preliminary results from a new randomized, placebo-controlled, crossover study, investigating the effects of aXivite[®] on high-intensity CrossFit performance and

recovery, was announced. The study was conducted by Dr. Pablo Jiménez Martínez and his team in Spain and is part of a government-funded doctoral research initiative aimed at enhancing performance through novel bioactive compounds. Early data confirms that aXivite[®] significantly improves strength, endurance, and recovery. Full study results we be presented and published shortly.

The information was submitted, through the care of the contact person below, for publication on 14 July 2025, at 08.30 AM CET.

Company contact:

Torsten Helsing, CEO, aXichem AB Phone: +46 706 863 355 Email: torsten.helsing@axichem.com

About aXichem

aXichem develops, patents and markets natural analogue industrial chemicals, i.e., synthetically produced substances that have similar and comparable properties to natural substances. The company's first product is phenylcapsaicin, which the company commercializes under two brands, aXiphen® and aXivite®, as an ingredient in animal feed and dietary supplements, respectively. The business is divided into three market areas with different applications for phenylcapsaicin: as an ingredient in feed for poultry, such as chicken and turkey; as an ingredient in food supplements for gut health, weight control and sports and exercise; and as an ingredient in food supplements for the bio-enhancement of curcumin and melatonin. aXichem is listed on the Nasdaq First North Growth Market. Certified advisor for aXichem is Västra Hamnen Corporate Finance AB.

More about aXichem at www.axichem.com.